Inotuzumab ozogamicin

(Besponsa®)

Besponsa®

Drug updated on 11/13/2023

Dosage Forminjectable (intravenous: 0.9 mg/vial)
Drug ClassCD22-directed antibody drug conjugates
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Product Monograph / Prescribing Information

Document TitleYearSource
Besponsa (inotuzumab ozogamicin) Prescribing Information.2018Pfizer Inc., Philadelphia, PA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines